Home
HelpTest Code PERA Preeclampsia sFlt-1/PIGF (Soluble fms-Like Tyrosine Kinase 1/ Placental Growth Factor) Ratio, Serum
Ordering Guidance
The test is indicated for use in pregnant women, with singleton pregnancies (gestational age 23 to 34+6/7 weeks) hospitalized for hypertensive disorders of pregnancy (preeclampsia, chronic hypertension with or without superimposed preeclampsia or gestational hypertension), within 2 weeks of presentation.
Specimen Required
Patient Preparation: For 24 hours before specimen collection, the patient should not receive intravenous heparin.
Supplies: Sarstedt Aliquot Tube, 5 mL (T914)
Collection Container/Tube:
Preferred: Serum gel
Acceptable: Red top
Submission Container/Tube: Plastic vial
Specimen Volume: 0.5 mL
Collection Instructions: Centrifuge and aliquot serum into a plastic vial.
Useful For
Aiding in risk assessment of patients with clinical signs and symptoms consistent with development of preeclampsia with severe features
This test is not intended for making a diagnosis of preeclampsia or preeclampsia with severe features.
This test is not a stand-alone test for monitoring of hypertensive disorders of pregnancy or for changing treatment, including medication.
Method Name
Immunofluorescent Assay (IFA)
Reporting Name
Preeclampsia sFlt-1/PlGF Ratio, SSpecimen Type
SerumSpecimen Minimum Volume
0.3 mL
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Serum | Frozen (preferred) | 180 days | |
| Refrigerated | 24 hours |
Reject Due To
| Gross hemolysis | OK |
| Gross lipemia | OK |
| Gross icterus | Reject |
Reference Values
<40
Interpretation
A sFlt-1/PlGF (soluble fms-like tyrosine kinase 1/placental growth factor) ratio will be reported as a unitless whole number. sFlt-1 and PlGF concentrations will not be individually reported.
The sFlt-1/PlGF ratio is indicated to be used as an aid in the management of the patient and are prognostic assays intended to stratify hospitalized patients in two risk groups (low risk and high risk of progression to preeclampsia with severe features within two weeks from presentation).
If the result of the sFlt-1/PlGF ratio is greater than or equal to 40, the pregnant woman is at high risk for progression to preeclampsia with severe features within 2 weeks of presentation.
If the result of the sFlt-1/PlGF ratio is less than 40, the pregnant woman is at low risk for progression to preeclampsia with severe features within 2 weeks of presentation.
The sFlt-1/PlGF ratio results should be used in conjunction with information available from clinical evaluations and other standard of care procedures. The test result is not to be used to replace clinical judgement. The clinical management should be dependent on the patient's healthcare provider's recommendations as inferred from their clinical status. Therefore, the test results should not be used as a deciding factor to change management plans, and especially not for decisions of pregnancy delivery or for patient discharge from hospital.
Day(s) Performed
Monday through Saturday
Report Available
1 to 3 daysPerforming Laboratory
Mayo Clinic Laboratories in Rochester
Test Classification
This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.CPT Code Information
0482U
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| PERA | Preeclampsia sFlt-1/PlGF Ratio, S | 74757-6 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| PERAT | sFlt-1/PlGF Ratio | 74757-6 |